UGT2B4: Difference between revisions
CSV import |
No edit summary |
||
| Line 1: | Line 1: | ||
'''UGT2B4''' is a member of the UDP-glucuronosyltransferase (UGT) family of enzymes, which are involved in the process of glucuronidation. This process is a major phase II metabolic pathway that facilitates the elimination of lipophilic xenobiotics and endogenous compounds by converting them into more water-soluble glucuronides. UGT2B4 is primarily expressed in the liver, but it is also found in other tissues such as the kidney and intestine. | '''UGT2B4''' is a member of the UDP-glucuronosyltransferase (UGT) family of enzymes, which are involved in the process of glucuronidation. This process is a major phase II metabolic pathway that facilitates the elimination of lipophilic xenobiotics and endogenous compounds by converting them into more water-soluble glucuronides. UGT2B4 is primarily expressed in the liver, but it is also found in other tissues such as the kidney and intestine. | ||
| Line 25: | Line 22: | ||
* [[Cytochrome P450]] | * [[Cytochrome P450]] | ||
* [[Pharmacogenomics]] | * [[Pharmacogenomics]] | ||
{{Enzyme-stub}} | {{Enzyme-stub}} | ||
[[Category:Enzymes]] | [[Category:Enzymes]] | ||
[[Category:Drug metabolism]] | [[Category:Drug metabolism]] | ||
[[Category:Human proteins]] | [[Category:Human proteins]] | ||
Latest revision as of 04:25, 2 December 2024
UGT2B4 is a member of the UDP-glucuronosyltransferase (UGT) family of enzymes, which are involved in the process of glucuronidation. This process is a major phase II metabolic pathway that facilitates the elimination of lipophilic xenobiotics and endogenous compounds by converting them into more water-soluble glucuronides. UGT2B4 is primarily expressed in the liver, but it is also found in other tissues such as the kidney and intestine.
Function[edit]
UGT2B4 plays a crucial role in the metabolism of a wide range of substrates, including steroids, bile acids, and various drugs. It catalyzes the transfer of glucuronic acid from the cofactor UDP-glucuronic acid to its substrates, thereby increasing their solubility and promoting their excretion in urine or bile.
Substrate Specificity[edit]
UGT2B4 has a broad substrate specificity, but it is particularly known for its role in the glucuronidation of bile acids such as chenodeoxycholic acid and lithocholic acid. It also metabolizes certain hormones and pharmaceuticals, contributing to the detoxification and clearance of these compounds from the body.
Genetic Variability[edit]
The UGT2B4 gene is subject to genetic polymorphisms, which can lead to variations in enzyme activity among individuals. These polymorphisms can affect drug metabolism and influence an individual's response to medication, potentially impacting drug efficacy and toxicity.
Clinical Significance[edit]
Alterations in UGT2B4 activity can have significant clinical implications. For instance, reduced activity of UGT2B4 may lead to the accumulation of toxic bile acids, contributing to liver diseases such as cholestasis. Additionally, variations in UGT2B4 activity can affect the pharmacokinetics of drugs metabolized by this enzyme, necessitating dose adjustments in certain patients.
Research and Development[edit]
Ongoing research is focused on understanding the regulation of UGT2B4 expression and activity, as well as its role in drug-drug interactions. Advances in this area could lead to improved strategies for personalized medicine, optimizing drug therapy based on an individual's UGT2B4 genotype.
